跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,300 条关于
“Focal Segmental Glomerular Sclerosis”
全部
13,300
临床试验
11,377
药物
156
机构
29
资讯
1,738
去年
FDA Confirms Proteinuria as Primary Endpoint for Dimerix's DMX-200 Phase 3 FSGS Trial
去年
FDA Accepts Sparsentan sNDA for Full Approval in Focal Segmental Glomerulosclerosis
去年
FILSPARI (sparsentan) Shows Clinical Benefit in IgAN and FSGS, Travere Therapeutics Reports
去年
Walden Biosciences Advances Kidney Disease Therapies with WAL0921 and WAL0623
10个月前
Processa Pharmaceuticals to Present Adaptive Phase 2/3 Study of PCS499 for Rare Kidney Disease FSGS at ASN Kidney Week 2025
去年
Sparsentan Demonstrates Efficacy in Treating Genetic FSGS, DUPLEX Trial Analysis Shows
去年
FDA Authorizes Emergency Compassionate Use of VAR 200 for Ultra-Rare ApoCII Amyloidosis
去年
Hydroxychloroquine Shows Promise for Kidney Protection in Primary Glomerular Disease and Lupus Nephritis
去年
Travere Therapeutics' Filspari Shows Sustained Benefit in IgAN and FSGS
2年前
Dimerix's First Patient Completes Phase 3 Trial and Enters DMX-200 Open Label Extension Study for Kidney Disease
第 1 页，共 174 页
上一页
下一页
